Document:

Exhibit
10.3

 

WARRANT
AGENT AGREEMENT

 

THIS
WARRANT AGENT AGREEMENT, dated as of December 22, 2022 (this “Agreement”), between 180 Life Sciences Corp., a Delaware
corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant
Agent”).

 

WHEREAS,
pursuant to the terms of a securities purchase agreement (the “Purchase Agreement”), dated December 20, 2022, by and
between the Company and Armistice Capital Master Fund Ltd., as the purchaser (the “Purchaser”), the Company sold and
issued (i) 215,000 shares of the Company’s common stock, $0.0001 par value (the “Common Stock”), (ii) pre-funded
warrants to purchase up to 1,499,286 shares of Common Stock at an exercise price of $0.0001 per Share and (iii) warrants (the “Warrants”)
to purchase up to 2,571,429 shares of Common Stock at an exercise price of $3.50 per Share (the “Warrant Shares”);

 

WHEREAS,
the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with
the registration, transfer, exchange, redemption and exercise of the Warrants;

 

WHEREAS,
the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

 

WHEREAS,
all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and
countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and
to authorize the execution and delivery of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.
Capitalized Terms. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the
Warrant.

 

2.
Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants,
and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set
forth in this Agreement.

 

3.
Warrants.

 

3.1
Form of Warrant. Each Warrant, together with the form of election to purchase Common Stock (“Notice of Exercise”)
and the form of assignment printed on the reverse thereof, shall be in the form of Exhibit A hereto, the provisions of which are incorporated
herein, and signed by, or bear the facsimile signature of, the Chief Executive Officer of the Company. In the event the person whose
facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant
before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.
The Warrants shall be registered securities and shall be initially evidenced by a global Warrant certificate (“Global Certificate”)
in the form of Annex A to this Agreement, which shall be deposited on behalf of the Company with a custodian for The Depository
Trust Company (“DTC”) and registered in the name of Cede & Co., a nominee of DTC. If DTC subsequently ceases to
make its settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding making arrangements for book-entry
settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, registration
in the name of Cede & Co., a nominee of DTC, the Company may instruct the Warrant Agent to provide written instructions to DTC to
deliver to the Warrant Agent for cancellation the Global Certificate, and the Company shall instruct the Warrant Agent to deliver to
the registered holder (as defined below) DTC definitive certificates in physical form evidencing such Warrants.

 

    

     

    

 

3.2
Effect of Countersignature. Unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant shall be
invalid and of no effect and may not be exercised by the holder thereof.

 

3.3
Registration.

 

3.3.1
Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”) for the registration of the
original issuance and registration of transfers of the Warrants. Any Person (as defined below) in whose name ownership of a beneficial
interest in the Warrants evidenced by a Global Certificate is recorded in the records maintained by DTC or its nominee shall be deemed
the “beneficial owner” thereof, provided that all such beneficial interests shall be held through a Participant (as defined
below), which shall be the registered holder of such Warrants. “Person” means an individual or corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency
or subdivision thereof) or other entity of any kind.

 

3.3.2
Issuance of Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue the Global Certificate and deliver
the Warrants in the DTC settlement system in accordance with written instructions delivered to the Warrant Agent by the Company. Ownership
of beneficial interests in the Book-Entry Warrants shall be shown on, and the transfer of such ownership shall be effected through, records
maintained (i) by DTC or its nominee for each Book-Entry Warrant; (ii) by institutions that have accounts with DTC (such institution,
with respect to a Warrant in its account, a “Participant”); or (iii) directly on the book-entry records of the Warrant
Agent with respect only to owners of beneficial interests that represent such direct registration. If the Warrants are not DTC eligible
as of the initial issuance date or DTC subsequently ceases to make its book-entry settlement system available for the Warrants, the Company
may instruct the Warrant Agent in writing regarding making other arrangements for book-entry settlement within ten (10) days after DTC
ceases to make its book-entry settlement available. In the event that the Company does not make alternative arrangements for book-entry
settlement within ten (10) days or the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in,
book-entry form, the Warrant Agent shall provide written instructions to DTC to deliver to the Warrant Agent for cancellation each Book-Entry
Warrant, and the Company shall instruct the Warrant Agent to deliver to DTC definitive certificates in physical form evidencing such
Warrants.

 

3.3.3
Beneficial Owner; Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent
may deem and treat the Person in whose name that Warrant shall be registered on the Warrant Register (the “Holder,”
which term shall include a Holder’s transferees, successors and assigns and a “Holder” shall include, if the Warrants
are held in “street name,” a Participant or a designee appointed by such Participant) as the absolute owner of such Warrant
for purposes of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by
any notice to the contrary. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Warrant Agent or any agent of
the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by DTC governing
the exercise of the rights of a holder of a beneficial interest in any Warrant. The rights of beneficial owners in a Warrant evidenced
by the Global Certificate shall be exercised by the Holder or a Participant through the DTC system, except to the extent set forth herein
or in the Global Certificate.

 

    2

     

    

 

4.
Terms and Exercise of Warrants.

 

4.1
Duration of Warrants. The Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be
exercisable as set forth in the Warrant.

 

4.2
Exercise of Warrants.

 

4.2.1
Payment. Subject to the foregoing and to Section 2(c) of the Warrant, the registered holder of a Warrant may exercise the Warrant
in whole or in part pursuant to Section 2 of the Warrant. Payment of the Exercise Price, may be made, at the option of the registered
holder, by wire transfer or by certified or official bank check in United States dollars, as set forth in the Warrant.

 

4.2.2
Notice of Exercise. The registered holder shall deliver the executed Notice of Exercise and the payment of the Exercise Price
as described herein. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required.

 

4.2.3
Cashless Exercise. If at the time of exercise, there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the registered holder, then upon receipt of a Notice of Exercise for
a cashless exercise as provided in Section 2(c) of the Warrant (“Cashless Exercise”), the Company will promptly calculate
and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise and deliver a copy
of the Notice of Exercise to the Warrant Agent, which shall issue such number of Warrant Shares in connection with such Cashless Exercise.
Any Warrants outstanding on the Termination Date will be automatically exercised via cashless exercise pursuant to Section 2 of the Warrant.

 

4.2.4
Issuance of Certificates. Upon the exercise of the Warrant pursuant to the terms of Section 2 of the Warrant, the Warrant Agent
shall cause the Warrant Shares underlying such Warrant to be delivered to or upon the order of the registered holder of such Warrant,
registered in such name or names as may be designated by such registered holder, by the date that is the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period following the date of exercise as aforesaid (the “Warrant
Share Delivery Date”). If the Company is then a participant in the DWAC system of the depositary and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the registered holder
or (B) the Warrant is being exercised via Cashless Exercise, then the Warrant Shares shall be transmitted by the Warrant Agent to the
registered holder by crediting the account of the registered holder’s broker with the depositary through its DWAC system. Notwithstanding
anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any registered holder fails to duly deliver
payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of
such registered holder’s Warrant as set forth in Section 4 hereof by the Warrant Share Delivery Date, the Warrant Agent will not
be obligated to deliver such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant
Share Delivery Date shall be deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant
Agent.

 

    3

     

    

 

4.2.5
New Warrants. In case the registered holder of any Warrant shall exercise fewer than all Warrants evidenced thereby, a new Warrant
evidencing the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued by the Warrant Agent to the
registered holder of such Warrant or to his duly authorized assigns in accordance with Section 2(d)(ii) of the Warrant, subject to the
provisions of Section 7.2 hereof.

 

4.2.6
Valid Issuance. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall
be validly issued, fully paid and nonassessable.

 

4.2.7
Date of Issuance. Each person in whose name any such certificate for shares of Common Stock is issued shall for all purposes be
deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the Exercise
Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a
date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at
the close of business on the next succeeding date on which the stock transfer books are open.

 

5.
Adjustments.

 

5.1
Adjustments to Warrants. The Exercise Price, the number of Warrant Shares and the number of Warrants outstanding are subject to
adjustment from time to time as provided in Section 3 of the Warrant. In the event that at any time, as a result of an adjustment made
pursuant to Section 3 of the Warrant, the registered holder of any Warrant thereafter exercised shall become entitled to receive any
shares of capital stock of the Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon
exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable
to the provisions with respect to the shares contained in Section 3 of the Warrant and the provisions of Sections 4 and 5 of this Agreement
with respect to the shares of Common Stock shall apply on like terms to any such other shares. All Warrants originally issued by the
Company subsequent to any adjustment made to the Exercise Price pursuant to the Warrant shall evidence the right to purchase, at the
adjusted Exercise Price, the number of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants,
all subject to further adjustment as provided herein.

 

    4

     

    

 

5.2
Notices of Changes in Warrant. Whenever the Exercise Price or the number of shares of Common Stock issuable upon the exercise
of each Warrant is adjusted as provided in Section 5.1 or 5.3, the Company shall give written notice thereof to the Warrant Agent, which
notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable
at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such
calculation is based. Upon the occurrence of an adjustment as provided in Section 5.1 or 5.3, then, in any such event, the Company shall
promptly deliver written notice by email to each registered holder setting forth the Exercise Price of each Warrant as so adjusted, any
resulting adjustment to the number of Warrant Shares and a brief statement of the facts requiring such adjustment. Failure to give such
notice, or any defect therein, shall not affect the legality or validity of such event.

 

5.3
No Fractional Shares. The Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute
stock certificates which evidence fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise
be required to be issued or distributed, the actual issuance or distribution in respect thereof shall be made in accordance with Section
2(d)(v) of the Warrant.

 

5.4
Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 5, and Warrants issued
after such adjustment may state the same Exercise Price and the same number of shares as is stated in the Warrants initially issued pursuant
to this Agreement.

 

6.
Transfer and Exchange of Warrants.

 

6.1
Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant in the
Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly medallion guaranteed and accompanied
by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall
be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled may be delivered by the Warrant Agent
to the Company from time to time upon request.

 

6.2
Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange
or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the registered
holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that
a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants
in exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer is exempt
from registration under the U.S. Securities Act of 1933, as amended, and indicating whether the new Warrants must also bear a restrictive
legend.

 

    5

     

    

 

6.3
Service Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

6.4
Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with
the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 6, and the Company, whenever
required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

7.
Other Provisions Relating to Rights of Registered Holders of Warrants.

 

7.1
No Rights as Stockholder. A Warrant does not entitle the registered holder thereof to any of the rights of a stockholder of the
Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote
or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company
or any other matter.

 

7.2
Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant
Agent may, on such terms as to indemnity or otherwise as they may in their discretion impose (which terms shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so lost, stolen, mutilated
or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly
lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3
Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued
shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

8.
Concerning the Warrant Agent and Other Matters.

 

8.1
Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or
the Warrant Agent in respect of the issuance or delivery of Warrant Shares, but the Company shall not be obligated to pay any transfer
taxes in respect of the Warrants or such shares.

 

8.2
Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1
Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and
be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company.
If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days
after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of the Warrant (who shall,
with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme
Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost.
Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the
laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York,
and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority.
After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations
of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed;
but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of
the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant
Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all
instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers,
rights, immunities, duties, and obligations.

 

    6

     

    

 

8.2.2
Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

8.2.3
Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant
Agent under this Agreement without any further act.

 

8.3
Fees and Expenses of Warrant Agent.

 

8.3.1
Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder
and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of
its duties hereunder.

 

8.3.2
Further Assurances. The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged
and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the
carrying out or performing of the provisions of this Agreement.

 

8.4
Liability of Warrant Agent.

 

8.4.1
Reliance on Company Statement. Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it
necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved
and established by a statement signed by the Chief Executive Officer or Chief Financial Officer of the Company and delivered to the Warrant
Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions
of this Agreement.

 

    7

     

    

 

8.4.2
Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The
Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable
counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant
Agent’s gross negligence, willful misconduct or bad faith.

 

8.4.3
Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the
validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company
of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required
under the provisions of Section 4 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of
the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation
or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant
or as to whether any shares of Common Stock will when issued be valid and fully paid and nonassessable.

 

8.5
Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same
upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of
Common Stock through the exercise of Warrants.

 

9.
Miscellaneous Provisions.

 

9.1
Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall
bind and inure to the benefit of their respective successors and assigns.

 

9.2
Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder
of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service,
addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

180
Life Sciences Corp.

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, California 94306

 

Any
notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on
the Warrant Agent shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another
address is filed in writing by the Company with the Warrant Agent) as follows:

 

Continental
Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, NY 10004-1561

Attn: Compliance Department

 

    8

     

    

 

Any
notice, sent pursuant to this Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed,
if sent by overnight courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on
the third day after registration or certification thereof.

 

9.3
Applicable Law. The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all respects
by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the
substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or
relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District
Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The
Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process
or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt
requested, postage prepaid, addressed to it at the address set forth in Section 9.2 hereof. Such mailing shall be deemed personal service
and shall be legal and binding upon the Company in any action, proceeding or claim.

 

9.4
Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the
provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto
and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition,
stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement
shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the
Warrants.

 

9.5
Examination of this Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant
Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent
may require any such holder to submit his, her or its Warrant for inspection by it.

 

9.6
Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7
Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect
the interpretation thereof.

 

9.8
Amendments. This Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of
curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other
provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that
the parties deem shall not adversely affect the interest of the registered holders. All other modifications or amendments, including
any amendment to increase the Exercise Price or shorten the exercise period, shall require the written consent of the registered holders
of a majority of the then outstanding Warrants.

 

9.9
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision
shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

[Signature
page follows]

 

    9

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	180 LIFE SCIENCES CORP.
	 	 	 
	 	By:	/s/
    Ozan Pamir         
	 	Name:  	Ozan Pamir
	 	Title:	CFO
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST
    COMPANY
	 	 	 
	 	By:	/s/
    Leicia Savinetti                       
	 	Name: 	 Leicia Savinetti
	 	Title:	 Vice
    President and Account AdministratorExhibit 10.4

 

LOCK-UP AGREEMENT

 

December ___, 2022

 

		Re:	Securities Purchase Agreement, dated as of December 20, 2022 (the “Purchase Agreement”),
between 180 Life Sciences Corp. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser”
and, collectively, the “Purchasers”)

 

Ladies and Gentlemen:

 

Defined terms not
otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Purchase
Agreement. Pursuant to Section 2.2(a) of the Purchase Agreement and in satisfaction of a condition of the Company’s obligations
under the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until 90 days after the Closing
Date (such period, the “Restriction Period”) the undersigned will not offer, sell, contract to sell, hypothecate, pledge
or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition
(whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any controlled
Affiliate of the undersigned or any person in privity with the undersigned or any controlled Affiliate of the undersigned), directly or
indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning
of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to, any shares
of Common Stock of the Company or securities convertible, exchangeable or exercisable into, shares of Common Stock of the Company beneficially
owned, held or hereafter acquired by the undersigned (the “Securities”). Beneficial ownership shall be determined in
accordance with Section 13(d) of the Exchange Act.

 

Notwithstanding
the foregoing, the undersigned may transfer any of the undersigned’s Securities as set forth in paragraphs (i) through (xi)
below provided that (1) in the case of paragraphs (i) through (vii), the Company receives a signed lock-up letter agreement in the
form of this Letter Agreement for the balance of the Restriction Period from each donee, trustee, distributee or transferee, as the case
may be, prior to such transfer, (2) in the case of paragraphs (i), (iii) and (iv), any such transfer shall not involve a disposition
for value, (3) in the case of paragraphs (i) through (v) and paragraph and (xi), such transfer is not required to be reported with
the Securities and Exchange Commission (the “Commission”) in accordance with the Exchange Act, and (4) in the
case of paragraphs (i) through (xi), neither the undersigned nor any donee, trustee, distributee or transferee, as the case may be,
voluntarily effects any public filing or report regarding such transfer:

 

	 	(i)	as a bona fide gift or gifts;

 

	 	(ii)	to any immediate family member or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this Letter Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

 

	 	(iii)	to any corporation, partnership, limited liability company, or other business entity all of the equity holders of which consist of the undersigned and/or the immediate family of the undersigned;

 

     

     

    

 

	 	(iv)	if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (a) to another corporation, partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned or (b) in the form of a distribution to limited partners, limited liability company members or stockholders of the undersigned;

 

	 	(v)	if the undersigned is a trust, to the beneficiary of such trust;

 

	 	
    (vi)

     
	by trust, will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned; provided that, if required, any public filing, report or announcement, including under Section 16 of the Exchange Act, shall clearly indicate in the footnotes thereto that the filing relates to the transfer of securities pursuant to a trust, will, other testamentary document or intestate succession;

 

	 	(vii)	to a spouse, former spouse, child or other dependent pursuant to a domestic relations order or pursuant to a settlement agreement in connection with a domestic relations matter; provided that, other than with respect to such a transfer done pursuant to a court order, the assignee or transferee thereof agrees to be bound in writing by the restrictions set forth herein;

 

	 	(viii) 	through the disposition or forfeiture of the undersigned’s shares to the Company to satisfy any income, employment or tax withholding and remittance obligations of the undersigned or the employer of the undersigned in connection with the vesting of restricted stock, restricted stock units or other incentive awards settled in shares of Common Stock held by the undersigned; provided that, if required, any public filing, report or announcement, including under Section 16 of the Exchange Act, shall clearly indicate in the footnotes thereto that the filing relates to the transfer of shares through the disposition or forfeiture of the undersigned’s shares to the Company to satisfy any income, employment or tax withholding and remittance obligations of the undersigned or the employer of the undersigned in connection with the vesting of restricted stock, restricted stock units or other incentive awards settled in shares held by the undersigned; 

 

	 	(ix)	pursuant to a plan, contract or instruction that satisfies all of the requirements of Rule 10b5-1 of the Exchange Act and that was in effect prior to the date hereof; provided that, if required, any public filing, report or announcement, including under Section 16 of the Exchange Act, shall clearly indicate in the footnotes thereto that the transfers were made pursuant to a plan meeting the requirements of Rule 10b5-1;

 

    2

     

    

 

	 	(x)	pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company’s Securities involving a change of control of the Company; provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Securities held by the undersigned shall remain subject to the provisions of this Letter Agreement; and

 

	 	(xi)	if the Securities were purchased in open market transactions after the Closing Date.

   

In addition, notwithstanding
the foregoing, this Letter Agreement shall not restrict the delivery of shares of Common Stock to the undersigned upon (i) the vesting
or exercise of any equity incentive awards granted under any employee benefit plan of the Company; provided that any shares of
Common Stock or Securities acquired in connection with any such vesting or exercise will be subject to the restrictions set forth in this
Letter Agreement, or (ii) the exercise of warrants; provided that such shares of Common Stock delivered to the undersigned in connection
with such exercise are subject to the restrictions set forth in this Letter Agreement.

 

Furthermore, the
undersigned may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such
plan may only be established if no public announcement or filing with the Commission, or other applicable regulatory authority, is made
in connection with the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common Stock is made pursuant
to such plan during the Restriction Period.

 

The undersigned
acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to the Company to complete
the transactions contemplated by the Purchase Agreement and the Company shall be entitled to specific performance of the undersigned’s
obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform
this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit
from the closing of the transactions contemplated by the Purchase Agreement.

 

This Letter Agreement may
not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned. This Letter
Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict
of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern
District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding
arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding,
any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an
inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the
Company at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Letter Agreement does not intend to create any relationship between the undersigned and any Purchaser and that no Purchaser
is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Letter Agreement.

 

This Letter Agreement shall
automatically terminate if the Purchase Agreement is terminated in accordance with its terms prior to the consummation of the transactions
contemplated thereby.

 

This Letter Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provisions hereof be enforced by, any other Person.

 

This Letter Agreement shall
be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into
a similar agreement for the benefit of the Company.

 

*** SIGNATURE PAGE FOLLOWS***

 

    3

     

    

 

This Letter Agreement may
be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.

 

	 	 
	Signature	 
	 	 
	 	 
	Print Name	 
	 	 
	 	 
	Position in Company, if any	 
	 	 
	Address for Notice:	 
	 	 
	 	 
	 	 

 

By signing below, the Company
agrees to enforce the restrictions on transfer set forth in this Letter Agreement.

 

	180 LIFE SCIENCES CORP.	 
	 	 
	By:	 	 
	Name:	           	 
	Title:	 	 

 

[Signature Page to Lock-Up Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]